Cover Image
市場調查報告書

Brintellix(重度憂鬱症)- 預測與市場分析

Brintellix (Major Depressive Disorder) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 305481
出版日期 內容資訊 英文 47 Pages
訂單完成後即時交付
價格
Back to Top
Brintellix(重度憂鬱症)- 預測與市場分析 Brintellix (Major Depressive Disorder) - Forecast and Market Analysis to 2023
出版日期: 2014年05月30日 內容資訊: 英文 47 Pages
簡介

重度憂鬱症(MDD)是世界最常見的精神疾病之一。MDD市場競爭激烈,有30個以上的上市產品可用於患者的治療上。憂鬱症市場上,在主力產品(Eli Lilly的Cymbalta、大塚製薬/BMS的Abilify)專利即將到期,抗憂鬱症藥品的新產品(Lundbeck/武田薬品工業的Brintellix)及未來有望的後期階段開發平台產品即將上市的當下,市場正在大大變化中。

本報告提供MDD的治療藥物Brintellix之調查分析,提供疾病概要和治療指南,競爭情形,產品資訊,銷售額預測等相關之系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
    • 病因
    • 病理生理學
  • 分類
  • 症狀和亞型
  • 預後
  • QOL

第4章 疾病的管理

  • 診斷和治療概要

第5章 競爭評估

  • 概要

第6章 Brintellix(Vortioxetine)

  • 概要
  • 功效
  • 安全性
  • SWOT分析
  • 預測

第7章 附錄

圖表

目錄
Product Code: GDHC422DFR

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.

Brintellix (vortioxetine) is a multimodal antidepressant that is indicated for the treatment of MDD and was co-developed by Lundbeck and Takeda. It gained FDA approval in October 2013 and EMA approval in December 2013. Brintellix launched in the US market in January 2014 and its launch in European markets is expected during the second half of 2014 (Lundbeck, press release, December 27, 2013).

Scope

  • Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Brintellix including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Brintellix for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Brintellix performance
  • Obtain sales forecast for Brintellix from 2013-2023 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification
  • 3.3. Symptoms and Subtypes of Major Depressive Disorder
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview

6. Brintellix (Vortioxetine)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed MDD Patients
    • 7.4.2. Percent of Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
    • 7.4.5. Generic Erosion
  • 7.5. Physicians and Specialists Included in this Study
  • 7.6. About the Authors
    • 7.6.1. Analyst
    • 7.6.2. Therapy Area Directors
    • 7.6.3. Global Head of Healthcare
  • 7.7. About GlobalData
  • 7.8. Disclaimer

List of Tables

  • Table 1: Classification and Criteria of Major Depressive Disorder (DSM-IV) and Major Depressive Episode (ICD-10)
  • Table 2: Subtypes of Major Depressive Disorder
  • Table 3: Severity of Depressive Episodes according to ICD-10 and DSM-IV Diagnostic Criteria
  • Table 4: Treatment Guidelines for Major Depressive Disorder
  • Table 5: Most Prescribed Drugs for MDD by Class in the 7MM and Australia, 2013
  • Table 6: Leading Treatments for MDD, 2013
  • Table 7: Product Profile - Brintellix
  • Table 8: Efficacy of Brintellix in Six-Week to Eight-Week Clinical Trials
  • Table 9: Safety of Brintellix - Five Most Frequently Reported Adverse Events
  • Table 10: Brintellix SWOT Analysis, 2014
  • Table 11: Global MDD Sales Forecasts ($m) for Brintellix, 2013-2023
  • Table 12: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons
  • Figure 2: Disease Management Model for Major Depressive Disorder
  • Figure 3: Major Depressive Disorder Treatment Algorithm
Back to Top